Inclusion Criteria:

- Histological confirmed advanced well differentiated carcinoma of the lung and thymus

- Patients of all treatment lines can be included

- At least one measurable lesion of disease on CT scan or MRI

- Radiological documentation of disease progression within 12 months prior to
randomization

- Adequate liver, renal and bone marrow function

- WHO Performance Status 0-2

Exclusion Criteria:

- Poorly differentiated neuroendocrine carcinoma

- Non-neuroendocrine thymoma

- Patients with severe functional disease requiring symptomatic treatment with
somatostatin analogs

- Prior therapy with mTOR inhibitors

- History of liver disease

- Baseline QTcF> 470 msec

- Uncontrolled diabetes mellitus despite adequate therapy

Other protocol-defined inclusion/exclusion criteria may apply.